2026-09-12T13:00:11-05:00 2025-12-31 334358135 SAX ADVISORS LLC 389 INTERPACE PARKWAY STE 3 PARSIPPANY NJ 07054 990 2025-01-01 920240717 EVERY CURE INC EVER 4842856568 3675 MARKET ST SUITE 200 PHILADELPHIA PA 19104 DAVID FAJGENBAUM CEO 4842856568 2026-09-12 1 MARQUS WHITE P00053187 9734726250 2026-09-10 2025 DAVID FAJGENBAUM 3675 MARKET ST SUITE 200 PHILADELPHIA PA 19104 34822357 0 X WWW.EVERYCURE.ORG X 2022 DE THE ORGANIZATION'S MISSION IS TO SAVE AND IMPROVE LIVES BY REPURPOSING DRUGS. 8 6 37 39 0 0 54182643 33527421 0 0 283565 1294936 0 0 54466208 34822357 2181501 2787334 0 0 3148613 6263984 0 0 765656 2104303 3082992 7434417 12134310 47031791 22688047 51613641 74089051 2337747 2166351 49275894 71922700 X EVERY CURE IS ON A MISSION TO SAVE AND IMPROVE LIVES BY REPURPOSING DRUGS, UTILIZING ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING TO SYSTEMATICALLY SCAN THE WORLD'S BIOMEDICAL KNOWLEDGE ACROSS ALL APPROVED DRUGS AND ALL KNOWN DISEASES TO IDENTIFY THE MOST PROMISING OPPORTUNITIES. THE ORGANIZATION'S MEDICAL TEAM OF PHYSICIANS AND RESEARCHERS EVALUATES AND VALIDATES THESE OPPORTUNITIES AND ADVANCES THE MOST PROMISING CANDIDATES THROUGH LABORATORY STUDIES AND CLINICAL TRIALS TO ENSURE EFFECTIVE THERAPIES REACH PATIENTS IN NEED. 0 0 6949376 2787334 AI TOOL DEVELOPMENT: IN 2025, EVERY CURE'S TECHNICAL TEAM CONTINUED TO BUILD AND ENHANCE ITS AI-PLATFORM TO SYSTEMATICALLY IDENTIFY HIGH-POTENTIAL DRUG REPURPOSING OPPORTUNITIES. THE TEAM DEVELOPED AND TESTED THREE MAIN METHODS OF RANKING REPURPOSING OPPORTUNITIES AT SCALE: GRAPH-BASED MODELING OF BIOLOGICAL AND CLINICAL RELATIONSHIPS, EXTRACTION OF EXISTING SCIENTIFIC EVIDENCE, AND ANALYSIS OF REAL-WORLD PATIENT DATA. TOGETHER, THESE APPROACHES GENERATED APPROXIMATELY 1,400 CANDIDATE DRUG REPURPOSING OPPORTUNITIES EACH MONTH FOR CLINICAL REVIEW BY EVERY CURE'S MEDICAL TEAM, SUBSTANTIALLY EXPANDING THE PIPELINE OF POTENTIAL REPURPOSED TREATMENTS THAT CAN BE EVALUATED TO SAVE AND IMPROVE PATIENTS' LIVES. 2056461 DRUG REPURPOSING RESEARCH AND DEVELOPMENT (SCIENTIFIC APPLICATION): AT THE END OF 2025, EVERY CURE HAD NINE ACTIVE DRUG REPURPOSING PROGRAMS SPANNING FROM ULTRA RARE TO COMMON DISEASES, UP FROM 5 IN 2024. SELECTION OF THE MOST PROMISING DRUG REPURPOSING OPPORTUNITIES FOR FURTHER ADVANCEMENT INVOLVES MEDICAL EXPERTS EVALUATING EXISTING KNOWLEDGE AND AI-GENERATED INSIGHTS. ADVANCEMENT OF THESE PROMISING REPURPOSING OPPORTUNITIES FROM DISCOVERY TO PATIENT IMPACT INCLUDES ACTIVITIES SUCH AS MANAGING PRE-CLINICAL STUDIES, REVIEWING REAL-WORLD EVIDENCE, PERFORMING CLINICAL TRIALS, AND DISSEMINATING KNOWLEDGE TO ENSURE ADOPTION. 151990 EDUCATION AND AWARENESS-RAISING ON DRUG REPURPOSING: EVERY CURE EDUCATES PHYSICIANS, RESEARCHERS, PATIENTS, POLICYMAKERS, AND THE GENERAL PUBLIC ABOUT THE POTENTIAL FOR DRUG REPURPOSING TO ACCELERATE CURES. EDUCATION AND OUTREACH ARE CENTRAL TO CREATING A SHIFT IN DRUG DISCOVERY AND THE PRACTICE OF MEDICINE, WHERE EXISTING THERAPIES ARE FULLY LEVERAGED FOR DISEASES BEYOND THEIR ORIGINAL APPROVALS. IN 2025, WE REACHED MILLIONS OF PEOPLE WITH OUR MISSION THROUGH SOCIAL MEDIA AND PRESS COVERAGE, INCLUDING A TED TALK BY OUR FOUNDER, HIGHLIGHTING THE STORY OF DRUG REPURPOSING AND EVERY CURE'S MISSION WHICH INCREASED VISIBILITY AND ENGAGEMENT WITH OUR WORK. WE HAVE DISSEMINATED SCIENTIFIC FINDINGS THROUGH PRESENTATIONS AT INTERNATIONAL SCIENTIFIC MEETINGS, INVITED TALKS AT RESEARCH INSTITUTIONS, AND PUBLICATION OF EDUCATIONAL CONTENT IN PROFESSIONAL OUTLETS TO INCREASE AWARENESS AMONG PHYSICIANS AND SCIENTISTS. THESE EDUCATIONAL ACTIVITIES INCREASED AWARENESS OF DRUG REPURPOSING AMONG HEALTHCARE PROFESSIONALS, RESEARCHERS, POLICYMAKERS, PATIENTS, AND THE PUBLIC, HELPING TO FOSTER COLLABORATION AND SUPPORT THE RESPONSIBLE ADVANCEMENT OF DRUG REPURPOSING ACROSS THE HEALTHCARE ECOSYSTEM. 9157827 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 1 1 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 20 0 1 37 1 0 0 0 0 0 0 0 0 0 0 0 0 X 8 6 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NY PA X MARY ZUCCATO 4842856568 3675 MARKET ST SUITE 200 PHILADELPHIA PA 19104 DAVID FAJGENBAUM CO-FOUNDER & PRESIDENT 40.00 X X 204042 0 4080 GRANT MITCHELL FORMER CEO & TREASURER 40.00 X X 88720 0 5956 TANIA SIMONCELLI VICE CHAIR & SECRETARY 1.00 X X 0 0 0 FREDA LEWIS-HALL DIRECTOR 1.00 X 0 0 0 JULIAN BAKER DIRECTOR 1.00 X 0 0 0 ROBERT MCDONALD DIRECTOR 1.00 X 0 0 0 JANET WOODCOCK DIRECTOR 1.00 X 0 0 0 ERIC HORVITZ DIRECTOR 1.00 X 0 0 0 ALEXANDER PAMPALONE CHIEF PHILANTHROPY OFFICER 40.00 X 336749 0 28971 MARY ZUCCATO CHIEF OPERATING OFFICER 40.00 X 277841 0 27186 CHARLOTTE HEMPSTEAD CHIEF PLATFORM OFFICER 40.00 X 244175 0 46158 MATTHEW GODDEERIS CHIEF SCIENTIFIC OFFICER 40.00 X 238598 0 22652 LEE LANCASHIRE HEAD OF DATA SCIENCE 40.00 X 204294 0 35444 PASCAL BROKMEIER HEAD OF ENGINEERING 40.00 X 189683 0 27687 LAURENS VIJNCK PRINCIPAL DATA ENGINEER 40.00 X 135235 0 27601 ELLIOTT SHARP DIRECTOR, PIPELINE STRATEGY 40.00 X 129821 0 22653 VANESSA ROSTICK DIRECTOR OF HR 40.00 X 134310 0 14321 2183468 0 262709 19 0 1 0 MRJENOVICH & BERTUCCI LTD 7055 VETERANS BLVD SUITE D BURR RIDGE IL 60527 ACCOUNTING SERVICES 195136 ONE TRIBE RECRUITMENT LLC 1523 BADGER CANYON LANE ARROYO GRANDE CA 93420 RECRUITING FIRM 167500 BEYOND ADVISERS 4826 STANLEY AVE DOWNERS GROVE IL 60515 LEGAL SERVICES 147500 PATZIK FRANK SAMOTNY LTD 200 S WACKER DR SUITE 2700 CHICAGO IL 60606 LEGAL SERVICES 106601 4 15887226 17640195 33527421 1294936 1294936 34822357 0 0 1294936 2787334 2787334 1525128 856698 305026 363404 3865458 3152308 518131 195019 130648 119110 11538 525787 448409 59813 17565 216963 142822 42430 31711 273920 273920 725216 366253 340563 18400 15443 5000 5967 4476 37526 20113 17055 358 495279 432443 40776 22060 290504 158080 73965 58459 324212 118599 182857 22756 2774 1765 1009 28309 28309 17655 141 17514 RESEARCH & DATA EXPENSE 483388 477947 5333 108 RECRUITMENT EXPENSE 198489 470 195814 2205 DUES AND SUBSCRIPTION 172748 41491 107634 23623 BAD DEBT 9000 9000 8529 535 2482 5512 12134310 9157827 2210827 765656 368460 1449591 16902303 38354290 29822610 29061064 63403 1300 40953 111963 87794 41063 63740 46731 4020121 4206426 332051 857686 51613641 74089051 2337747 1721840 0 444511 2337747 2166351 X 48675894 42262863 600000 29659837 49275894 71922700 51613641 74089051 X 22688047 20862 -62103 X 0 1 X 1 0 X 316125 2433649 54182643 33527421 90459838 316125 2433649 54182643 33527421 90459838 28601361 61858477 9736 283565 1294936 1588237 92048075 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 87794 41063 46731 46731 OPERATING LEASE 444511 444511 X 34988223 20862 207107 -62103 165866 34822357 0 34822357 12341417 207107 207107 12134310 0 12134310 PART X, LINE 2: THE ORGANIZATION IS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. IN ADDITION, THE ORGANIZATION QUALIFIES FOR THE CHARITABLE CONTRIBUTION DEDUCTION UNDER SECTION 170(B)(1)(A) AND HAS BEEN CLASSIFIED AS AN ORGANIZATION THAT IS NOT A PRIVATE FOUNDATION UNDER SECTION 509(A)(2). THE ORGANIZATION IS ALSO EXEMPT FROM STATE INCOME TAXES WITHIN THE STATES THAT THE ORGANIZATION OPERATES. THE ORGANIZATION HAS APPLIED THE PROVISIONS OF THE FASB'S ASC 740-10, ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES. UNDER ASC 740-10, NONPUBLIC ENTERPRISES, INCLUDING NONPROFIT ORGANIZATIONS, ARE REQUIRED TO RECORD A TAX LIABILITY WHEN SUBSTANTIAL UNCERTAINTIES EXIST AS TO WHETHER CERTAIN INCOME IS EXEMPT FROM FEDERAL, STATE AND LOCAL INCOME TAX. AS OF DECEMBER 31, 2025, THE ORGANIZATION HAD NO SUBSTANTIAL UNCERTAIN INCOME TAX POSITIONS. PART XI, LINE 2D - OTHER ADJUSTMENTS: LOSS ON IMPAIRMENT OF ASSETS HELD FOR SALE -62,103. UNITED KINGDOM 1 16 PROGRAM SERVICES RESEARCH AND DEVELOPMENT 2410737 NETHERLAND 1 2 PROGRAM SERVICES RESEARCH AND DEVELOPMENT 425668 2 18 0 0 2 18 2836405 0 2836405 0 0 0 0 0 0 1 PENN STATE UNIVERSITY 180 POLLOCK ROAD 308 OLD MAIN UNIVERSITY PARK PA 16802 246000376 501 (C) (3) 371233 0 LEAD THE DEVELOPMENT OF ADVANCED COMPUTATIONAL TOOLS THE SCRIPPS RESEARCH INSTITUTE 10550 NORTH TORREY PINES ROAD LA JOLLA CA 92037 330435954 501 (C) (3) 492388 0 INTEGRATE ITS BIOTHINGS EXPLORER PLATFORM INTO EVERY CURE'S KNOWLEDGE GRAPH UNIVERSITY OF ALABAMA BIRMINGHAM 801 5TH AVE S BIRMINGHAM AL 35233 636005396 501 (C) (3) 309630 0 CONTRIBUTE SPECIALIZED BIOMEDICAL DATA AND EXPERTISE UNIVERSITY OF NORTH CAROLINA 104 AIRPORT DRIVE SUITE 2200 CHAPEL HILL NJ 275991350 566001393 501 (C) (3) 1222086 0 CO-LEAD DEVLEOPMENT OF THE INTEGRATION LAYER THAT CONNECTES DIVERSE DATASETS INSTITUTE FOR SYSTEMS BIOLOGY 401 TERRY AVE NORTH SEATTLE WA 98109 912003593 501 (C) (3) 391997 0 CURATE, EVALUATE AND INTEGRATE LARGE BIOMEDICAL DATASETS 5 PART I, LINE 2: EVERY CURE IDENTIFIES AND SELECTS GRANT RECIPIENTS BASED ON THEIR UNIQUE, SPECIALIZED EXPERTISE IN SPECIFIC FIELDS OF BIOMEDICAL RESEARCH. THESE INSTITUTIONS WERE CHOSEN TO SERVE AS SUBCONTRACTORS UNDER OUR ARPA-H OTA AGREEMENT TO EXECUTE DEFINED RESEARCH OBJECTIVES. EVERY CURE MONITORS THE DISTRIBUTED FUNDS AND ENSURES THEIR USE FOR PROPER PURPOSES BY TRACKING MILESTONE COMPLETION WITH DIRECT OVERSIGHT FROM THE EVERY CURE PROGRAM TEAM. THE PRIMARY BENEFIT OF THIS WORK ACCRUES TO THE GENERAL PUBLIC, NOT THE FEDERAL GOVERNMENT. X X X 0 0 0 0 0 0 0 0 0 ALEXANDER PAMPALONE CHIEF PHILANTHROPY OFFICER 336749 0 0 0 0 0 12038 0 16933 0 365720 0 0 0 MARY ZUCCATO CHIEF OPERATING OFFICER 254841 0 23000 0 0 0 10125 0 17061 0 305027 0 0 0 CHARLOTTE HEMPSTEAD CHIEF PLATFORM OFFICER 211152 0 33023 0 0 0 7325 0 38833 0 290333 0 0 0 MATTHEW GODDEERIS CHIEF SCIENTIFIC OFFICER 238598 0 0 0 0 0 6636 0 16016 0 261250 0 0 0 LEE LANCASHIRE HEAD OF DATA SCIENCE 197249 0 7045 0 0 0 6129 0 29315 0 239738 0 0 0 PASCAL BROKMEIER HEAD OF ENGINEERING 175754 0 13929 0 0 0 16695 0 10992 0 217370 0 0 0 DAVID FAJGENBAUM CO-FOUNDER & PRESIDENT 204042 0 0 0 0 0 4080 0 0 0 208122 0 0 0 LAURENS VIJNCK PRINCIPAL DATA ENGINEER 127222 0 8013 0 0 0 16612 0 10989 0 162836 0 0 0 ELLIOTT SHARP DIRECTOR, PIPELINE STRATEGY 121434 0 8387 0 0 0 3895 0 18758 0 152474 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS PRESENTED DURING A MEETING OF THE BOARD OF DIRECTORS TO EACH MEMBER. IT IS REVIEWED, DISCUSSED, AND APPROVED. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION ROUTINELY REVIEWS ANY SITUATION THAT ARISES THAT MAY CAUSE A CONFLICT OF INTEREST FORM 990, PART VI, SECTION B, LINE 15 EVERY CURE ENSURES THAT EXECUTIVE COMPENSATION IS REASONABLE AND COMPETITIVE BY FOLLOWING A FORMAL, DOCUMENTED PROCESS. THE INDEPENDENT DIRECTORS OF THE BOARD REVIEW AND APPROVE EXECUTIVE COMPENSATION, IN LINE WITH EVERY CURE'S DEFINED COMPENSATION PHILOSOPHY, ON AN ANNUAL BASIS. IN ACCORDANCE WITH THE COMPENSATION PHILOSOPHY, THE GROUP RELIES ON ROBUST SETS OF COMPARABLE DATA, INCLUDING COMPENSATION STUDIES AND BENCHMARKING FROM REPUTABLE DATABASES AND PUBLICLY AVAILABLE FORM 990 FILINGS FROM SIMILAR ORGANIZATIONS. THE ENTIRE PROCESS, FROM DATA REVIEW TO THE FINAL DECISION, IS DOCUMENTED IN THE OFFICIAL MEETING MINUTES. FORM 990, PART VI, SECTION C, LINE 19 A PACKET IS AVAILABLE UPON REQUEST AT THE ENTITY'S OFFICE. FORM 990, PART XI, LINE 9: LOSS ON IMPAIRMENT OF ASSETS HELD FOR SALE -62,103.